Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Wolfe has downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) to underperform from peer perform as it issues a contrarian view ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

Cardiomyopathies are diseases of the heart muscle. This group of pathological conditions includes dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic ...